From 1 July 2026, a clarification in the Swedish Medicines Act has further defined the role of legal representatives in clinical trials.
The clarification specifically reinforces the legal representative's responsibility to safeguard the individual’s personal interests.
While subtle, this update strengthens:
• Ethical oversight
• Patient protection
• Clear accountability in consent processes
These types of regulatory refinements are a key part of maintaining trust in clinical research. To read more, go to Läkemedelslagen (215:315; 7 kap. 3§).
Are you planning an upcoming clinical study? Contact us to discuss your needs. From standalone services to helping you design and conduct your entire study, our team of experts support you in translating evolving regulations into practical approaches for clinical research.
